Varenicline Blocks 2*-nAChR-Mediated Response and Activates 4*-nAChR-Mediated Responses in Mice In Vivo

A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (1909) · JAMA · doi:10.1001/jama.1909.02550020033007 · Cited by 7,865 · see citing works

Drug Metabolism and Disposition

(2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12259_4 · Cited by 2,518 · see citing works

Varenicline:  An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation

Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930 · see citing works

Guidelines on nicotine dose selection for in vivo research

Matta, S. G., Balfour, D. J., Benowitz, N. L., Boyd, R. T., Buccafusco, J. J., Caggiula, A. R., Craig, C. R., Collins, A. C., Damaj, M. I., Donny, E. C., et al. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0441-0 · Cited by 824 · see citing works

Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain

Picciotto, M. R., Zoli, M., Léna, C., Bessis, A., Lallemand, Y., LeNovère, N., Vincent, P., Pich, E. M., Brûlet, P., & Changeux, J.-P. (1995) · Nature · doi:10.1038/374065a0 · Cited by 668 · see citing works

Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors

Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558 · see citing works

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533 · see citing works

Mice Deficient in the α7 Neuronal Nicotinic Acetylcholine Receptor Lack α-Bungarotoxin Binding Sites and Hippocampal Fast Nicotinic Currents

Orr‐Urtreger, A., Göldner, F. M., Saeki, M., Lorenzo, I., Goldberg, L. B., Biasi, M. D., Dani, J. A., Patrick, J. W., & Beaudet, A. L. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-23-09165.1997 · Cited by 494 · see citing works

Subunit Composition and Pharmacology of Two Classes of Striatal Presynaptic Nicotinic Acetylcholine Receptors Mediating Dopamine Release in Mice

Salminen, O., Murphy, K. L., McIntosh, J. M., Drago, J., Marks, M. J., Collins, A. C., & Grady, S. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1526 · Cited by 401 · see citing works

Multiorgan Autonomic Dysfunction in Mice Lacking the β2 and the β4 Subunits of Neuronal Nicotinic Acetylcholine Receptors

Xu, W., Orr‐Urtreger, A., Nigro, F., Gelber, S. E., Sutcliffe, C. B., Armstrong, D. L., Patrick, J. W., Role, L. W., Beaudet, A. L., & Biasi, M. D. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-21-09298.1999 · Cited by 283 · see citing works

Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis

Mineur, Y. S., & Picciotto, M. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.004 · Cited by 277 · see citing works

METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRO

Obach, R. S., Reed‐Hagen, A. E., Krueger, S. S., Obach, B. J., O’Connell, T. N., Zandi, K. S., Miller, S., & Coe, J. W. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006767 · Cited by 199 · see citing works

Acetylcholine Receptor (AChR) α5 Subunit Variant Associated with Risk for Nicotine Dependence and Lung Cancer Reduces (α4β2)2α5 AChR Function

Kuryatov, A., Berrettini, W., & Lindstrom, J. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.066357 · Cited by 171 · see citing works

Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence

Rollema, H., Shrikhande, A., Ward, K., Tingley III, F., Coe, J., O'Neill, B., Tseng, E., Wang, E., Mather, R., Hurst, R., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00682.x · Cited by 162 · see citing works

A comparative study of the disposition of nicotine and its metabolites in three inbred strains of mice.

Petersen, D. R., Norris, K. J., & Thompson, J. A. (1984) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07789-x · Cited by 160 · see citing works

Sazetidine-A, A Novel Ligand That Desensitizes α4β2 Nicotinic Acetylcholine Receptors without Activating Them

Xiao, Y., Fan, H., Musachio, J. L., Wei, Z.-L., Chellappan, S. K., Kozikowski, A. P., & Kellar, K. J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027318 · Cited by 141 · see citing works

Preclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects on reward, mood and cognition

Rollema, H., Hajós, M., Seymour, P. A., Kozak, R., Majchrzak, M. J., Guanowsky, V., Horner, W. E., Chapin, D. S., Hoffmann, W. E., Johnson, D. E., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.033 · Cited by 117 · see citing works

Single‐Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers

Faessel, H. M., Smith, B. J., Gibbs, M. A., Gobey, J. S., Clark, D. J., & Burstein, A. H. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006290669 · Cited by 104 · see citing works

Structural differences determine the relative selectivity of nicotinic compounds for native α4β2*-, α6β2*-, α3β4*- and α7-nicotine acetylcholine receptors

Grady, S. R., Drenan, R. M., Breining, S. R., Yohannes, D., Wageman, C. R., Fedorov, N. B., McKinney, S., Whiteaker, P., Bencherif, M., Lester, H. A., et al. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.01.013 · Cited by 98 · see citing works

Ligands selective for α4β2 but not α3β4 or α7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat

Smith, J. W., Mogg, A. J., Tafi, E., Peacey, E., Pullar, I. A., Szekeres, P. G., & Tricklebank, M. D. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0596-8 · Cited by 94 · see citing works

Nicotinic Partial Agonists Varenicline and Sazetidine-A Have Differential Effects on Affective Behavior

Turner, J. R., Castellano, L. M., & Blendy, J. A. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166280 · Cited by 88 · see citing works

Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation

McCallum, S. E., Collins, A. C., Paylor, R. E., & Marks, M. J. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0076-6 · Cited by 72 · see citing works

Varenicline Is a Potent Agonist of the Human 5-Hydroxytryptamine3 Receptor

Lummis, S. C. R., Thompson, A. J., Bencherif, M., & Lester, H. A. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185306 · Cited by 71 · see citing works

Mecamylamine blockade of nicotine responses: Evidence for two brain nicotinic receptors

Collins, A. C., Evans, C. B., Miner, L. L., & Marks, M. J. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90518-6 · Cited by 67 · see citing works

Varenicline for smoking cessation: efficacy, safety, and treatment recommendations

Ebbert, J. O. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s10620 · Cited by 67 · see citing works

Activation and Inhibition of Mouse Muscle and Neuronal Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes

Papke, R. L., Wecker, L., & Stitzel, J. A. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.164566 · Cited by 67 · see citing works

A test battery for measuring nicotine effects in mice

Marks, M. J., Romm, E., Bealer, S. M., & Collins, A. C. (1985) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(85)90577-5 · Cited by 65 · see citing works

Nicotinic agonists differ in activation and desensitization of 86Rb+ efflux from mouse thalamic synaptosomes.

Marks, M. J., Robinson, S. F., & Collins, A. C. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13086-3 · Cited by 65 · see citing works

Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.

Raybuck, J. D., Portugal, G. S., Lerman, C., & Gould, T. J. (2008) · Behavioral Neuroscience · doi:10.1037/a0012601 · Cited by 62 · see citing works

Electrophysiological Perspectives on the Therapeutic Use of Nicotinic Acetylcholine Receptor Partial Agonists

Papke, R. L., Trocmé, C., Guendisch, D., Rubaiy, S. A. A. A., & Bloom, S. A. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.177485 · Cited by 61 · see citing works

Chronic corticosterone administration modulates nicotine sensitivity and brain nicotinic receptor binding in C3H mice

Pauly, J. R., Grun, E. U., & Collins, A. C. (1990) · Psychopharmacology · doi:10.1007/bf02244047 · Cited by 59 · see citing works

Null mutant analysis of responses to nicotine: Deletion of β2 nicotinic acetylcholine receptor subunit but not α7 subunit reduces sensitivity to nicotine-induced locomotor depression and hypothermia

Tritto, T., McCallum, S. E., Waddle, S., Hutton, S. R., Paylor, R. E., Collins, A. C., & Marks, M. J. (2004) · Nicotine & Tobacco Research · doi:10.1080/14622200310001656966 · Cited by 57 · see citing works

[3H]A-585539 [(1 S,4 S)-2,2-Dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a Novel High-Affinity α7 Neuronal Nicotinic Receptor Agonist: Radioligand Binding Characterization to Rat and Human Brain

Anderson, D. J., Bunnelle, W. H., Surber, B. W., Du, J. Y., Surowy, C. S., Tribollet, E., Marguerat, A., Bertrand, D., & Gopalakrishnan, M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130062 · Cited by 52 · see citing works

Effect of the α4β2∗ nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in β2 knock-out mice with selective re-expression of the β2 subunit in the ventral tegmental area

Repérant, C., Pons, S., Dufour, E., Rollema, H., Gardier, A. M., & Maskos, U. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.10.007 · Cited by 41 · see citing works

Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats

Zaniewska, M., McCreary, A. C., Stefański, R., Przegaliński, E., & Filip, M. (2008) · Synapse · doi:10.1002/syn.20564 · Cited by 32 · see citing works

The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: Differences in α4β2 nicotinic receptor activation

Cunningham, C. S., & McMahon, L. R. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.12.003 · Cited by 24 · see citing works

Central 5-HT3 receptor-induced hypothermia in mice: Interstrain differences and comparison with hypothermia mediated via 5-HT1A receptor

Naumenko, V. S., Kondaurova, E. M., & Popova, N. K. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.09.005 · Cited by 24 · see citing works

Ondansetron and fluoxetine reduce sleep apnea in mice lacking monoamine oxidase A

Real, C. C., Seif, I., Adrien, J., & Escourrou, P. (2009) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2009.07.003 · Cited by 20 · see citing works

Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3′-(substituted phenyl)deschloroepibatidine analogs

Carroll, F. I., Yokota, Y., Ma, W., Lee, J. R., Brieaddy, L. E., Burgess, J. P., Navarro, H. A., Damaj, M. I., & Martin, B. R. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.027 · Cited by 16 · see citing works

In vivo effects of 3-iodocytisine: Pharmacological and genetic analysis of hypothermia and evaluation of chronic treatment on nicotinic binding sites

Zambrano, C. A., Marks, M. J., Cassels, B. K., & Maccioni, R. B. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.05.004 · Cited by 11 · see citing works

Varenicline overdose in a teenager – a clinical pharmacology perspective

Rollema, H., Faessel, H. M., & Williams, K. E. (2009) · Clinical Toxicology · doi:10.1080/15563650902970689 · Cited by 6 · see citing works

Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum

Bordia, T., Hrachova, M., Chin, M., McIntosh, J. M., & Quik, M. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194852 · Cited by 70 · see citing works

Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice

Biała, G., & Staniak, N. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.04.022 · Cited by 23 · see citing works

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533 · see citing works

Functional Interactions of Varenicline and Nicotine With nAChR Subtypes Implicated in Cardiovascular Control

Rollema, H., Russ, C., Lee, T. C., Hurst, R. S., & Bertrand, D. (2014) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntt208 · Cited by 14 · see citing works

The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats

O’Connor, E. C., Parker, D., Rollema, H., & Mead, A. N. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1739-5 · Cited by 118 · see citing works

Neuronal Nicotinic Acetylcholine Receptors as Pharmacotherapeutic Targets for the Treatment of Alcohol Use Disorders

Chatterjee, S., & Bartlett, S. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966597 · Cited by 99 · see citing works